10-KT: Zeo ScientifiX Reports Transition Period Results, Faces Going Concern Doubt

Zeo ScientifiX, Inc. filed its Form 10-K for the transition period ending June 30, 2026, reporting increased revenues but also substantial doubt regarding its ability to continue as a going concern.

Summary

• Zeo ScientifiX, Inc. has filed its Form 10-K for the eight-month transition period from November 1, 2025, to June 30, 2026, following a change in its fiscal year end.
• The company reported increased revenues of $5.87 million for the period, up from $3.10 million in the prior comparable period, driven by allogenic biologic products.
• Despite revenue growth, the company incurred a net loss of $5.07 million for the period, contributing to a significant accumulated deficit of $72.81 million.
• Auditors have expressed substantial doubt about the company's ability to continue as a going concern.
• The company is involved in several legal proceedings, including a significant ongoing case with Neurovive Holding Co., LLC.
• Zeo ScientifiX is focused on regenerative medicine and has benefited from recent state laws expanding access to certain stem cell therapies.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to significant accumulated deficits, substantial doubt about the company's ability to continue as a going concern, and ongoing legal proceedings.

Positives

• Revenues increased by 89.4% to $5.87 million for the eight-month transition period ended June 30, 2026, compared to $3.10 million for the same period in the prior year.
• Gross profit margin remained strong at 80.8% for the period.
• The company has secured $2.05 million in a private offering from November 2025 to June 2026.
• Strategic partnerships and collaborations are being pursued to advance product commercialization.
• The company holds two issued U.S. patents for its Organicell line of products and proprietary techniques.

Negatives

• The company incurred a net loss of $5.07 million for the eight-month transition period ended June 30, 2026, and has an accumulated deficit of $72.81 million as of that date.
• Auditors have expressed substantial doubt about the company's ability to continue as a going concern.
• General and administrative expenses increased by 49.6% to $10.17 million for the period, largely due to increased stock-based compensation costs.
• The company has limited cash on hand and relies on external financing.
• The company is involved in ongoing litigation with Neurovive Holding Co., LLC, which could result in significant damages.

Risks

• Substantial doubt exists regarding the company's ability to continue as a going concern due to significant losses and accumulated deficits.
• The company's strategy to commercialize stem cell and regenerative medicine products under recently enacted state laws may not be successful and remains subject to federal regulatory risk.
• The company depends on its officers and key personnel, and the loss of their services could harm its business.
• The company faces intense competition from established companies with greater resources.
• The company's ability to protect its intellectual property is crucial and uncertain.
• The company is subject to extensive and costly FDA regulations, and failure to comply could result in severe sanctions.
• The company's common stock is subject to penny stock rules, limiting liquidity and potentially reducing its value.
• The company's operations are subject to ongoing legal proceedings, which could result in significant financial and operational impacts.

Future Outlook

The company anticipates continued revenue growth driven by expanding sales of its allogenic biologic products and leveraging new state laws that permit access to certain stem cell therapies. However, it expects to continue incurring substantial losses and negative operating cash flows for the foreseeable future and will require additional capital to fund operations, product development, and clinical studies.

Management Comments

• The Company believes that the enactment of these laws represents an emerging state-level regulatory framework that could expand physician and patient access to regenerative medicine therapies.
• The Company believes that the expansion of state laws permitting access to certain non-FDA-approved stem cell and regenerative medicine therapies could increase demand from patients seeking treatments not otherwise available, physicians seeking to incorporate these therapies, and patients who historically traveled abroad.
• The Company believes that its established manufacturing infrastructure, specialized laboratory capabilities, and relationships with licensed healthcare professionals position it to participate in the continued expansion of regenerative medicine and the broader evolution toward preventive, personalized, and longevity-focused healthcare.
• Management believes that the combination of the Companys existing commercial activities, specialized manufacturing infrastructure, scientific capabilities, established physician relationships, and expanding technology development strategy provides a foundation for long-term growth and competitive differentiation.

Industry Context

StockSavvy.ai notes that Zeo ScientifiX operates in the rapidly growing regenerative medicine market, which is projected to reach $49.32 billion by 2030 in the U.S. The company's strategy leverages evolving state regulations that permit access to certain non-FDA-approved therapies, a trend that could significantly impact market dynamics and patient access.

Comparison to Industry Standards

• The U.S. regenerative medicine market was valued at approximately $16.81 billion in 2023 and is projected to reach $49.32 billion by 2030, with a CAGR of 16.72%. Zeo ScientifiX aims to capture a portion of this growth.
• The U.S. cell therapy market is projected to reach approximately $10.34 billion by 2030, with a CAGR of 21.18%. Zeo ScientifiX's focus on cellular therapies aligns with this segment's growth.
• The company competes with numerous players in the regenerative medicine and aesthetics space, including Kimera Labs, MiMedx Group, Inc., and others, facing intense competition and the need for continuous innovation.
• The company's reliance on state-level regulatory frameworks for certain products contrasts with the broader industry's pursuit of FDA approval for traditional biologics, presenting a unique strategic approach.

Legal Proceedings

• Neurovive Holding Co., LLC, Paragon Medical Group, LLC, and Dr. David Buechner filed a complaint asserting claims for breach of contract, breach of fiduciary duty, misappropriation of trade secrets, fraud, promissory estoppel, unjust enrichment, and conversion.
• The company is defending against claims related to a former employment agreement with Dr. Howard Golub, which was settled and dismissed.
• Exotropin filed a complaint concerning a Sales Representative Agreement, which was settled and dismissed with prejudice.
• BioXtek sought to terminate a Binding MOU and Joint Venture, leading to litigation initiated by the Company against BioXtek for breach of contract and other claims, with counterclaims filed by BioXtek.

Related Party Transactions

• The Company sold products to a management services organization (MSO) in which Dr. George Shapiro has an indirect economic interest.
• The Company sold products to a medical practice in which Dr. George Shapiro has an economic interest.
• The Company sold its Membership Units in Exotropin to Purchasers, including Greyt Ventures LLC (a principal shareholder) and Skycrest Holdings, LLC (a former principal shareholder).
• The Company formed Serephon LLC with Ian Bothwell (CEO/CFO), Dr. George Shapiro (CMO), and Greyt Ventures LLC, with the Company holding a 50% interest and agreeing to supply biologic products.
• Stock compensation expenses were recognized for awards granted to officers, directors, and related parties.

Stakeholder Impact

• Shareholders face potential dilution from future issuances of equity securities and the risk of a decline in stock price due to market overhang.
• Creditors may be impacted if the company defaults on outstanding indebtedness or is forced into bankruptcy.
• Employees' job security may be affected by the company's going concern issues and potential need to scale back operations.
• Customers may be impacted by potential disruptions in product supply or quality control issues.
• Suppliers may face financial difficulties or an inability to borrow money, impacting their ability to purchase products or pay for them.

Next Steps

• Continue ongoing research and data gathering to support publishing peer-reviewed outcomes for ZEO's products.
• Advance clinical research by leveraging data collected from providers treating specific indications under new state stem cell laws.
• Seek accelerated approval and reimbursement where available for product applications.
• Identify and consummate strategic relationships and acquisition targets to enhance growth.
• Develop and supply new products and services to support healthcare providers.
• Increase sales of products compliant with FDA regulations and/or New Stem Cell Laws.
• Continue efforts to strengthen market awareness of the Company and its product offerings.
• Maintain compliance with existing and anticipated changes to FDA regulations.

Key Dates

Recommendation

The company's financial condition presents significant risks, including substantial doubt about its ability to continue as a going concern, a large accumulated deficit, and ongoing litigation. While revenues have increased, the persistent net losses and reliance on external financing, coupled with the inherent risks in the regenerative medicine sector and regulatory uncertainties, suggest a high level of risk for investors. The potential for dilution and the limited trading market for its stock further contribute to a negative outlook.

Keywords

regenerative medicine, stem cell therapy, biopharmaceutical, extracellular vesicles, exosomes, clinical stage, FDA regulation, Zofin